Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 461.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,335 shares of the company’s stock after purchasing an additional 9,316 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Wave Life Sciences were worth $57,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. M28 Capital Management LP increased its position in Wave Life Sciences by 4.7% during the fourth quarter. M28 Capital Management LP now owns 7,373,413 shares of the company’s stock worth $37,236,000 after buying an additional 328,913 shares during the period. Laurion Capital Management LP boosted its stake in Wave Life Sciences by 5.1% during the 3rd quarter. Laurion Capital Management LP now owns 871,500 shares of the company’s stock worth $5,011,000 after purchasing an additional 42,662 shares during the period. Newtyn Management LLC grew its position in Wave Life Sciences by 2.0% during the 3rd quarter. Newtyn Management LLC now owns 510,000 shares of the company’s stock worth $2,932,000 after purchasing an additional 10,000 shares during the last quarter. Wellington Management Group LLP increased its stake in Wave Life Sciences by 4.3% in the third quarter. Wellington Management Group LLP now owns 264,885 shares of the company’s stock valued at $1,523,000 after purchasing an additional 10,830 shares during the period. Finally, TD Asset Management Inc raised its holdings in shares of Wave Life Sciences by 26.5% in the fourth quarter. TD Asset Management Inc now owns 205,746 shares of the company’s stock valued at $1,039,000 after buying an additional 43,054 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Trading Up 4.1 %

Shares of NASDAQ WVE traded up $0.19 on Monday, reaching $4.85. 503,794 shares of the company traded hands, compared to its average volume of 831,054. The stock has a market capitalization of $593.08 million, a PE ratio of -8.82 and a beta of -1.12. Wave Life Sciences Ltd. has a fifty-two week low of $3.15 and a fifty-two week high of $7.67. The company has a 50 day moving average of $5.56 and a 200 day moving average of $5.18.

Wave Life Sciences (NASDAQ:WVE) last issued its earnings results on Wednesday, March 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $29.06 million during the quarter, compared to analyst estimates of $23.30 million. During the same quarter in the previous year, the business posted ($0.47) EPS. As a group, research analysts expect that Wave Life Sciences Ltd. will post -0.94 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 15,630 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total transaction of $96,437.10. Following the sale, the chief financial officer now directly owns 33,921 shares in the company, valued at approximately $209,292.57. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 31.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

WVE has been the subject of a number of analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $5.00 price objective on shares of Wave Life Sciences in a research report on Thursday, March 7th. Truist Financial reiterated a “buy” rating and set a $17.00 target price on shares of Wave Life Sciences in a research report on Monday, April 1st. HC Wainwright raised their price target on Wave Life Sciences from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Finally, StockNews.com cut Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 18th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.